PACKAGE LEAFLET: INFORMATION FOR THE USER
Aciclovir TEDEC 25 mg/ml solution for infusion EFG
Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.
Contents of the pack:
Aciclovir belongs to the pharmacotherapeutic group of antivirals active against herpes virus.
This medicine is indicated in:
Do not use Aciclovir Tedec:
Warnings and precautions
Consult your doctor or pharmacist before starting to use aciclovir:
Consult your doctor, even if any of the above circumstances have occurred to you in the past.
Other medicines and Aciclovir Tedec
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
The safety of this medicine in pregnant women has not been established, and it will only be used in cases where the benefit-risk assessment by your doctor advises its use.
Aciclovir is excreted in breast milk.
Driving and using machines
No data are available to restrict this activity.
Aciclovir Tedec contains sodium and sodium metabisulfite
This medicine contains 39.3 mg of sodium (main component of table/cooking salt) per ampoule. This is equivalent to 1.965% of the maximum recommended daily sodium intake for an adult.
This medicine may cause severe allergic reactions and bronchospasm (sudden feeling of suffocation) because it contains sodium metabisulfite.
Follow exactly the administration instructions of this medicine indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Remember to use your medicine.
This medicine and its administration method have been prescribed exclusively for you. You should never give it to others or use it for other types of disorders.
Your doctor will indicate the dose and duration of your treatment with intravenous aciclovir. In acute infections caused by herpes simplex virus, 5 days of treatment are usually sufficient, but the duration of treatment will depend on the severity of the infection, the patient's condition, and response to treatment. The treatment of herpetic encephalitis and neonatal herpes simplex usually lasts 10 days. The duration of prophylactic administration of intravenous aciclovir will be determined by the duration of the risk period.
The recommended dose is:
Adults
Normal renal function
Patients with infections caused by herpes simplex virus (except herpetic encephalitis) or varicella-zoster virus: dose of 5 mg/kg, every 8 hours.
Immunocompromised patients with infections caused by varicella-zoster virus or with herpetic encephalitis: dose of 10 mg/kg, every 8 hours.
Impaired renal function
The administration of intravenous aciclovir in patients with impaired renal function should be performed with caution.
The following modifications are recommended in case of renal dysfunction:
Creatinine clearance (ml/min) | Original dose | Adjusted dose |
25 – 50 | 5 mg/kg every 8 hours 10 mg/kg every 8 hours | 5 mg/kg every 12 hours 10 mg/kg every 12 hours |
10 – 25 | 5 mg/kg every 8 hours 10 mg/kg every 8 hours | 5 mg/kg every 24 hours 10 mg/kg every 24 hours |
0 – 10 | 5 mg/kg every 8 hours 10 mg/kg every 8 hours | 2.5 mg/kg every 24 hours 5 mg/kg every 24 hours after dialysis |
Use in children and adolescents
The dose of intravenous aciclovir for children between 3 months and 12 years is calculated based on body surface area.
Children with infections caused by herpes simplex virus or varicella-zoster virus: dose of 250 mg/m2 of body surface area, every 8 hours.
Immunocompromised children with varicella-zoster virus or children with herpetic encephalitis: dose of 500 mg/m2 of body surface area, every 8 hours.
Children with impaired renal function require appropriate modifications according to the degree of impairment.
The dose of aciclovir in neonates (herpes simplex): 10 mg/kg every 8 hours.
Use in elderly patients
The dose should be reduced in patients with renal insufficiency.
If you think the action of aciclovir is too strong or too weak, tell your doctor.
If you use more Aciclovir Tedec than you should
If you have used a higher dose than you should, consult your doctor or pharmacist immediately. In the administration of single doses up to 80 mg/kg, no side effects have been observed. Intravenous aciclovir is dialyzable.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested. Bring this leaflet with you.
If you forget to use Aciclovir Tedec
Do not administer a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some patients treated with intravenous aciclovir have presented the following symptoms: increased liver enzymes, decreased hematological indices, rash, and fever, nausea, and vomiting.
Disorders of the nervous system: agitation, confusion, tremor, difficulty moving, difficulty speaking, confusion or imagining things (hallucinations), convulsions, somnolence, encephalopathy (brain disorder), coma. These effects are generally reversible and usually appeared in patients with renal impairment or predisposing factors.
In some patients, a rapid and reversible increase in blood urea or creatinine levels was observed, which is believed to be due to high plasma levels of the drug and the patients' hydration status. Therefore, it is essential that the hydration level is adequate.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Before dilution: No special storage conditions are required.
After dilution: The validity period of this medicine after dilution is 8 hours at 25°C and 24 hours at 2-8°C.
Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month indicated.
Composition of Aciclovir Tedec
The active substance is aciclovir. Each ampoule contains 250 mg of aciclovir.
The other components (excipients) are: sodium metabisulfite (E-223), sodium hydroxide, sodium citrate (E-331), hydrochloric acid, water for injectable preparations, and nitrogen.
Appearance of the product and pack contents
Aciclovir Tedec 25 mg/ml is a solution for infusion. It is presented in white glass ampoules. The solution is a clear, colorless, or pale yellow liquid. Each pack contains 5 ampoules. It is also presented in a clinical pack of 50 ampoules.
Marketing authorization holder and manufacturer
Meiji Pharma Spain, S.A.
Avda. de Madrid, 94
28802 Alcalá de Henares, Madrid (Spain)
Date of the last revision of this leaflet: May 2021
Other sources of information
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es.
--------------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals
The solution should be administered only by intravenous route and continuously but very slowly, so that it is administered over a period of not less than one hour.
If necessary, it is recommended to dilute immediately before use. The unused solution should be discarded. If visible turbidity or crystallization appears before or during infusion, the solution should be rejected.
Method of administration
Undiluted intravenous infusion:
The solution is administered using a controlled-rate infusion pump over a period of not less than one hour.
Infusion with dilution:
The solution can be diluted for administration by infusion. The dilution is made totally or partially, according to the necessary dose, adding and mixing it with at least 50 ml of infusion solution, to obtain a solution with a maximum concentration of 0.5% (250 mg/50 ml). The contents of 2 ampoules (500 mg of aciclovir) can be added to 100 ml of infusion solution, and if the required dose is higher than 500 mg, a second volume of infusion solution can be used.
This medicine is compatible with the following solutions:
It should be shaken vigorously to ensure perfect mixing.
After accidental intravenous injection of aciclovir, severe inflammation may appear in the extravascular tissue, sometimes followed by ulcers. Infusion using mechanical pumps poses greater risks than gravity infusion. Phlebitis and inflammation at the infusion site may occur.